Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)
Innate Pharma's (IPHA) quarterly Non-Current Assets came in at $18.6 million in Q4 2025, down 31.12% YoY from $27.1 million in Q4 2024, and down 41.12% on a QoQ basis from $31.6 million in Q2 2025.
Innate Pharma (IPHA) Non-Current Assets (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Non-Current Assets data on file, last reported at $18.6 million in Q4 2025.
- Quarterly Non-Current Assets fell 31.12% year-over-year to $18.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.6 million (down 31.12% YoY) and the FY2025 annual result came in at $18.6 million, down 31.12% from the prior year.
- Non-Current Assets declined to $18.6 million in Q4 2025, from $31.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $164.4 million in Q2 2021 to a low of $18.6 million in Q4 2025.
- A 5-year average of $70.7 million and a median of $51.2 million in 2023 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 7.44% in 2021, down 99.9% in 2021.
- Tracing IPHA's Non-Current Assets over 5 years: stood at $147.8 million in 2021, then sank by 53.05% to $69.4 million in 2022, then tumbled by 57.88% to $29.2 million in 2023, then fell by 7.47% to $27.1 million in 2024, then plunged by 31.12% to $18.6 million in 2025.
- The last three Non-Current Assets figures came in at $18.6 million (Q4 2025), $31.6 million (Q2 2025), and $27.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 18.06 Bn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | 18.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.64 Mn |
| Jun 30, 2025 | 31.65 Mn |
| Dec 31, 2024 | 27.05 Mn |
| Jun 30, 2024 | 42.97 Mn |
| Dec 31, 2023 | 29.24 Mn |
| Jun 30, 2023 | 59.45 Mn |
| Dec 31, 2022 | 69.41 Mn |
| Jun 30, 2022 | 115.92 Mn |
| Dec 31, 2021 | 147.85 Mn |
| Jun 30, 2021 | 164.42 Mn |
| Dec 31, 2020 | 159.73 Mn |
| Jun 30, 2020 | 169.38 Bn |
| Dec 31, 2019 | 181.26 Mn |
| Dec 31, 2018 | 151.43 Mn |
| Dec 31, 2017 | 142.00 Mn |